Cerebrospinal Fluid Proteomics in Friedreich Ataxia Reveals Markers of Neurodegeneration and Neuroinflammation

Clinical trials in rare diseases as Friedreich ataxia (FRDA) offer special challenges, particularly when multiple treatments become ready for clinical testing. Regulatory health authorities have developed specific pathways for “orphan” drugs allowing the use of a validated biomarker for initial appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Imbault, Virginie, Dionisi, Chiara, Naeije, Gilles, Communi, David, Pandolfo, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326443/
https://www.ncbi.nlm.nih.gov/pubmed/35911978
http://dx.doi.org/10.3389/fnins.2022.885313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326443/
https://www.ncbi.nlm.nih.gov/pubmed/35911978
http://dx.doi.org/10.3389/fnins.2022.885313

Ejemplares similares